Clinical Context
A typical patient is a 12–17 year old with newly diagnosed stage 1 type 1 diabetes mellitus at high risk of progression, or an individual identified with multiple autoantibodies and preserved C-peptide, referred to an endocrinology specialty clinic for disease-modifying therapy. The clinician orders J9381 (injection, teplizumab-mzwv, 5 mcg) as part of a multi-dose induction and maintenance regimen. The patient presents to an outpatient infusion center or hospital-based infusion clinic staffed by an endocrinologist, pediatric endocrinologist, or infusion nurse. Pre-infusion workflow includes verification of diagnosis, informed consent, baseline vital signs, documentation of current medications and allergies, review of prior laboratory results (including complete blood count and liver function tests), and establishment of IV access or subcutaneous administration per product labeling.
During each administration visit, the medication is prepared by pharmacy with appropriate lot tracking and compound labeling; the dose is confirmed against the patient’s weight and the product strength. The nurse administers J9381 per protocol, monitors for infusion reactions and vital sign changes for the recommended observation period, and documents the administration time, dose, lot number, route, and any adverse events. Follow-up visits include serial monitoring of clinical response, glucose control, and routine safety labs. Billing uses J9381 units based on the vial strength and institutional billing guidance, and may include applicable modifiers for unusual circumstances or payer-specific requirements.